Publications

June 2007
Teaching Note

Endo Pharmaceuticals Series (TN)

By: Richard G. Hamermesh, Brian DeLacey and Erin Seefeld

Keywords: Information

May 2007 (Revised September 2008)
Case

Biocon Limited

By: Krishna G. Palepu and Ananth Chepuri

Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details

Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India

February 2007 (Revised April 2010)
Case

Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics

By: Robert S. Huckman, Gary P. Pisano and Mark Rennella

Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details

Keywords: Decision Making; Measurement and Metrics; Business Processes; Organizational Structure; Research and Development; Science-Based Business; Creativity; Pharmaceutical Industry

January 2007 (Revised January 2007)
Background Note

Note on the U.S. Food and Drug Administration

By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller

Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details

Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

2007
Chapter

Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business

By: Rohit Deshpandé and Zoe Chance

Keywords: Health Disorders; Poverty; Product Marketing; Customers; Pharmaceutical Industry; Pharmaceutical Industry

November 2006
Case

Competitive Headaches (A): The Analgesic Wars

By: Dennis A. Yao

Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details

Keywords: Market Entry and Exit; Competition; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry

November 2006 (Revised May 2025)
Case

Eli Lilly: Developing Cymbalta

By: Elie Ofek and Ron Laufer

Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details

Keywords: Decision Choices and Conditions; Marketing Strategy; Product Launch; Product Development; Research and Development; Pharmaceutical Industry

November 2006 (Revised November 2007)
Case

Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.

By: David J. Collis and Troy Smith

The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details

Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States

November 2006
Case

Selling Biovail Short

By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia

Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details

Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada

November 2006 (Revised May 2007)
Supplement

Corporate Venture Capital at Eli Lilly

By: Richard G. Hamermesh

Keywords: Management; Business Ventures; Pharmaceutical Industry

2006
Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details

Keywords: Science; Business Ventures; Biotechnology Industry

Find at Harvard

October 2006
Teaching Note

Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)

By: Lynn S. Paine

Keywords: Pharmaceutical Industry; Argentina

September 2006
Teaching Note

Corporate Venture Capital at Eli Lilly (TN)

By: Richard G. Hamermesh and Erin Seefeld

Keywords: Venture Capital; Pharmaceutical Industry

September 2006 (Revised March 2010)
Case

Teva Pharmaceutical Industries, Ltd

By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras

How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details

Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; India; Israel